SANTA CLARA, Calif., April 16, 2013 /PRNewswire/ -- Finesse Solutions, Inc., a manufacturer of measurement and control solutions for life sciences process applications, announced the signing of a Distribution Agreement with ATMI, Inc. (NASDAQ: ATMI), a global technology company and a leader in single-use process solutions. Over the last two years, and after several collaborative projects, the relationship between the companies has gained in strategic importance.
This agreement will allow both companies to offer customers seamless support for single-use bioreactor systems enabled by Finesse SmartSystems™, and ATMI's single-use Integrity® PadReactor™ bioreactor. The solution combines the optimized mixing and gas transfer performance of the space-efficient PadReactor system with the industry's leading bioreactor control platform and single-use sensors, namely, state-of-the-art TruFluor™ sensors for pH and dissolved oxygen and TruTorr™ sensors for pressure. The integrated system couples ATMI LifeScience's Integrity PadReactor bioreactor with Finesse's G3-series SmartControllers™ and TruBio® 4.X DV software, which are pre-configured for controlling process parameters such as pH, dissolved oxygen, temperature, agitation, gas/liquid flow and auxiliary analog inputs/loops.
The integrated ATMI-Finesse bioreactor system can be purchased in a single transaction with follow-on application and technical support from both ATMI and Finesse. Under the terms of the agreement, Finesse will offer fully-integrated turnkey systems for upstream bioprocessing. Additionally, ATMI will provide all post-point-of-sale customer requirements for PadReactor hardware and disposables while Finesse will support and service the controller, sensors and software."Based on the DeltaV® control platform from Emerson, Finesse controllers allow users to scale their processes seamlessly from 1L lab-scale R&D bioreactors into cGMP single-use process trains having volumes up to 2,000L. By integrating our measurement and control solutions with the PadReactor system, Finesse will be able to offer a superior solution to its customer base for the production of recombinant proteins or vaccines. The end results will include suspension cell configurations as well as the most effective and productive system for micro-carrier based processes in the industry," stated Barbara Paldus, CEO of Finesse. Jeffery Craig, LifeSciences Global Director, Business Development at ATMI added, "Specifically designed to meet the needs of cell culturists, ATMI's PadReactor system is perfectly suited to process development, clinical material supply and flexible GMP manufacturing. The innovative, cube-shaped bioreactor vessel, which offers functionality that is comparable or better than classical stirred tank bioreactors, includes a single-use bag integrating an internal low-shear mixing paddle and sparger system. It is considerable end-user value that all ATMI bags are made with our in-house produced TK8 film which is designed specifically for cell culture and bioprocess applications. .The reactor, available in sizes ranging from 25L to 1200L, has been engineered to work in harmony with Finesse's cGMP-capable, highly configurable SmartSystems, which feature comprehensive functionality combined with easy process configuration and display." For more information on the turnkey bioreactor system, please contact ATMI LifeSciences or Finesse representatives.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts